4.4 Article

Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET

Journal

MOLECULAR IMAGING AND BIOLOGY
Volume 12, Issue 6, Pages 616-625

Publisher

SPRINGER
DOI: 10.1007/s11307-010-0315-z

Keywords

Epidermal growth factor receptor (EGFR); Small animal PET; Tyrosine kinase (TK) inhibitors

Funding

  1. Italian Ministry of University and Scientific Research
  2. Fondazione Cassa di Risparmio of Bologna (CARISBO)
  3. Italian Ministry of Health

Ask authors/readers for more resources

The in vivo evaluation of three modified polyethylene glycol (PEG)-anilinoquinazoline derivatives labeled with I-124, F-18, and C-11 as potential positron emission tomography (PET) bioprobes for visualizing epidermal growth factor receptor (EGFR) in cancer using small animal PET. Xenograft mice with the human glioblastoma cell lines U138MG (lacking EGFR expression) and U87MG.wtEGFR (transfected with an overexpressing human wild-type EGFR gene) were used. Static and dynamic PET imaging was conducted for all three PEGylated compounds. Tumor necrosis, microvessel density, and EGFR levels were evaluated by histopathology and enzyme-linked immunosorbent assay. Nineteen animal models were generated (two U138MG, three U87MG, 14 with both U138MG and U87MG bilateral masses). In static images, a slight increase in tracer uptake was observed in tumors, but in general, there was no retention of tracer uptake over time and no difference in uptake between U138MG and U87MG masses. In addition, no significant uptake was demonstrated in dynamic scans of the F-18-PEG tracer. No necrosis was present except in four animals. MVD was 9.6 and 48 microvessels/x400 field in the U138GM and U87GM masses, respectively (p = 0.00008). Similarly, the microvessel grades were generally higher in the U87GM group (p = 0.002). Total EGFR amount was higher in U87MG than U138MG masses (p = 0.001), but the ratio of activated (pY1068) to total EGFR did not differ (p = 0.95). PEGylated tracers labeled with C-11, I-124, and F-18 showed no significant difference in uptake between U138MG and U87MG glioblastoma xenograft mice. The tracer binding with EGFR could be influenced by activation of the tyrosine kinase portion of the receptor which was similar in U138MG and U87MG. Despite these results, these tracers should be investigated in animal models with mutant EGFR genes to determine whether aberrant receptor function plays a role in tumor uptake.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma

Marianna Carrabotta, Maria Antonella Laginestra, Giorgio Durante, Caterina Mancarella, Lorena Landuzzi, Alessandro Parra, Francesca Ruzzi, Lisa Toracchio, Alessandra De Feo, Veronica Giusti, Michela Pasello, Alberto Righi, Pier-Luigi Lollini, Emanuela Palmerini, Davide Maria Donati, Maria Cristina Manara, Katia Scotlandi

Summary: CIC-DUX4-rearranged sarcomas, specifically Capicua-double homeobox 4 (CIC-DUX4)-rearranged sarcomas (CDS), are rare and aggressive tumors that require specific therapeutic approaches. This study identified a unique HMGA2/IGF2BP/IGF2/IGF1R/AKT/mTOR axis in CDS, indicating sensitivity to combined treatments with trabectedin and PI3K/mTOR inhibitors. The development of representative experimental models (PDXs and PDX-derived cell lines) has highlighted the potential of AKT/mTOR inhibitors and trabectedin in combating this lethal cancer.

CANCER RESEARCH (2022)

Article Oncology

Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity

Tommaso Balestra, Maria Cristina Manara, Maria Antonella Laginestra, Michela Pasello, Alessandra De Feo, Cristian Bassi, Clara Guerzoni, Lorena Landuzzi, Pier-Luigi Lollini, Davide Maria Donati, Massimo Negrini, Mauro Magnani, Katia Scotlandi

Summary: The modulation of CD99 in Ewing sarcoma may alter transcriptional dysregulation and affect the development of the tumor by controlling the zyxin-GLI1 axis.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Oncology

Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis

Katsuhiro Togami, Sun Sook Chung, Vikas Madan, Christopher A. G. Booth, Christopher M. Kenyon, Lucia Cabal-Hierro, Justin Taylor, Sunhee S. Kim, Gabriel K. Griffin, Mahmoud Ghandi, Jia Li, Yvonne Y. Li, Fanny Angelot-Delettre, Sabeha Biichle, Michael Seiler, Silvia Buonamici, Scott B. Lovitch, Abner Louissaint, Elizabeth A. Morgan, Fabrice Jardin, Pier Paolo Piccaluga, David M. Weinstock, Peter S. Hammerman, Henry Yang, Marina Konopleva, Naveen Pemmaraju, Francine Garnache-Ottou, Omar Abdel-Wahab, H. Phillip Koeffler, Andrew A. Lane

Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia primarily occurring in males, and the mutations in X chromosome gene ZRSR2 are associated with impaired dendritic cell function and predisposition to leukemic transformation.

CANCER DISCOVERY (2022)

Article Cell Biology

Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma

Francesca Chiarini, Francesca Paganelli, Tommaso Balestra, Cristina Capanni, Antonietta Fazio, Maria Cristina Manara, Lorena Landuzzi, Stefania Petrini, Camilla Evangelisti, Pier-Luigi Lollini, Alberto M. Martelli, Giovanna Lattanzi, Katia Scotlandi

Summary: Lamin A plays a significant role in Ewing Sarcoma by affecting cell migration and invasiveness. Low expression of Lamin A is associated with increased aggressiveness and metastatic load in patients. This effect is linked to altered nuclear envelope proteins and increased nuclear retention of YAP/TAZ. Overexpression of Lamin A or pharmacological modulation of its maturation can prevent cell invasiveness and improve therapeutic strategies for Ewing Sarcoma.

CELL DEATH & DISEASE (2022)

Article Genetics & Heredity

Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs

Line J. Manceau, Julien E. Richard Albert, Pier-Luigi J. Lollini, Maxim V. C. E. Greenberg, Pascale J. Gilardi-Hebenstreit, Vanessa E. Ribes

Summary: The chimeric proteins PAX3-FOXO1 and PAX7-FOXO1, derived from chromosomal translocations, exhibit distinct genomic occupancy and transcriptional activity, leading to different pathological manifestations in alveolar rhabdomyosarcoma.

PLOS GENETICS (2022)

Article Oncology

CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality

Carlo Sorrentino, Luigi D'Antonio, Stefania Livia Ciummo, Cristiano Fieni, Lorena Landuzzi, Francesca Ruzzi, Simone Vespa, Paola Lanuti, Lavinia Vittoria Lotti, Pier Luigi Lollini, Emma Di Carlo

Summary: IL30 plays a crucial role in the development and progression of prostate cancer by regulating tumor driver genes and immunity-related genes. Targeting IL30 using CRISPR/Cas9-mediated therapy shows promise for clinical application.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Article Oncology

ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis

Michela Pasello, Anna Maria Giudice, Camilla Cristalli, Maria Cristina Manara, Caterina Mancarella, Alessandro Parra, Massimo Serra, Giovanna Magagnoli, Florencia Cidre-Aranaz, Thomas G. P. Grunewald, Carla Bini, Pier-Luigi Lollini, Alessandra Longhi, Davide Maria Donati, Katia Scotlandi

Summary: The study reveals that high expression of ABCA6 in Ewing sarcoma (EWS) is associated with a favorable outcome in patients. It functions as a tumor suppressor by regulating cholesterol levels and inhibiting IGF1R/AKT/MDM2 signaling, leading to reduced cell migration and increased sensitivity to chemotherapy. These findings support the use of ABCA6 as a biomarker for EWS progression and the consideration of statins as adjuvant drugs.

CELLULAR ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine

Francesca Ruzzi, Arianna Palladini, Stine Clemmensen, Anette Strobaek, Nicolaas Buijs, Tanja Domeyer, Jerzy Dorosz, Vladislav Soroka, Dagmara Grzadziela, Christina Jo Rasmussen, Ida Busch Nielsen, Max Soegaard, Maria Sofia Semprini, Laura Scalambra, Stefania Angelicola, Lorena Landuzzi, Pier-Luigi Lollini, Mette Thorn

Summary: The ES2B-C001 vaccine shows promising preclinical activity in the treatment of HER-2(+) breast cancer, effectively inhibiting tumor growth and metastasis. Vaccination induces strong antibody responses and does not cause cytokine storms. These results provide a basis for further human clinical studies.

BIOMEDICINES (2022)

Correction Oncology

ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis (Sept, 10.1007/s13402-022-00713-5, 2022)

Michela Pasello, Anna Maria Giudice, Camilla Cristalli, Maria Cristina Manara, Caterina Mancarella, Alessandro Parra, Massimo Serra, Giovanna Magagnoli, Florencia Cidre-Aranaz, Thomas G. P. Grunewald, Carla Bini, Pier-Luigi Lollini, Alessandra Longhi, Davide Maria Donati, Katia Scotlandi

CELLULAR ONCOLOGY (2022)

Review Oncology

Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research

Lorena Landuzzi, Francesca Ruzzi, Pier-Luigi Lollini, Katia Scotlandi

Summary: Synovial sarcoma is a rare malignant tumor characterized by t(X;18) translocation encoding the SS18-SSX fusion gene, which interacts with BAF enhancer and polycomb repressor complexes to regulate gene transcription. Different experimental in vivo models for synovial sarcoma research include transgenic mouse models, patient-derived xenografts, and cell lines. These models have contributed to identifying vulnerabilities and developing new therapies for synovial sarcoma.

CANCERS (2023)

Article Oncology

Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis

Giuseppe Visani, Maryam Etebari, Fabio Fuligni, Antonio Di Guardo, Alessandro Isidori, Federica Loscocco, Stefania Paolini, Mohsen Navari, Pier Paolo Piccaluga

Summary: Using next generation sequencing, this study found that genetic lesions characteristic of primary myelofibrosis occur at an early stage of hematopoietic stem cell differentiation. This sheds light on the complex transformation of pluripotent precursors in the development of the disease.

CANCERS (2023)

Article Oncology

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience

Elisabetta Setola, S. Benini, A. Righi, G. Gamberi, E. Carretta, C. Ferrari, S. Avnet, E. Palmerini, G. Magagnoli, M. Gambarotti, P. L. Lollini, M. Cesari, S. Cocchi, A. Paioli, A. Longhi, K. Scotlandi, M. A. Laginestra, D. M. Donati, N. Baldini, T. Ibrahim

Summary: This study found a higher frequency of IDH mutations in G3 CCBC compared to G2. No significant differences in overall survival, relapse-free survival, and progression-free survival were observed based on the mutational status. After relapse, a higher rate of G3 was observed in IDH mutated CCBC.

BMC CANCER (2023)

Review Oncology

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma

Lorena Landuzzi, Maria Cristina Manara, Laura Pazzaglia, Pier-Luigi Lollini, Katia Scotlandi

Summary: Synovial sarcoma (SyS) is a rare aggressive soft tissue sarcoma with a unique genetic signature. The majority of patients are initially diagnosed with localized disease, but metastatic relapse is common and advanced stages have a poor prognosis. This review summarizes current treatments and highlights the potential of new epigenetic and immunological strategies. Accurate patient selection based on genetic and tumor immune microenvironment signatures is crucial.

CANCERS (2023)

Article Oncology

Single-Step IGHV Next-Generation Sequencing Detects Clonality and Somatic Hypermutation in Lymphoid Malignancies: A Phase III Diagnostic Accuracy Study

Anna Gazzola, Mohsen Navari, Claudia Mannu, Riccardo Donelli, Maryam Etebari, Pier Paolo Piccaluga

Summary: This study compared the diagnostic accuracy of the first commercially available next-generation sequencing (NGS) approaches with the current gold standard methods for evaluating immunoglobulin heavy chain gene rearrangements. The results showed that NGS-based clonality and somatic hypermutation analyses gave comparable results to conventional Sanger sequencing.

CANCERS (2023)

Review Biochemistry & Molecular Biology

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy

Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, Arianna Palladini, Stefania Angelicola, Chiara Cappello, Olga Maria Pittino, Patrizia Nanni, Pier-Luigi Lollini

Summary: Cancer vaccines are being studied to prevent and treat cancers. Prophylactic vaccines for virus-caused cancers are already approved and used globally, while therapeutic cancer vaccines still need further development. Virus-like particles (VLPs) are protein structures designed to mimic viruses and can trigger immune responses. This review provides an overview of preventive VLP-based vaccines approved worldwide for HBV and HPV infections, and evaluates their effectiveness in preventing virus-caused cancers. It also summarizes preclinical and early clinical data on VLP-based cancer vaccines, focusing on HER-2-positive breast cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

No Data Available